Discounted Cash Flow
Harmony Biosciences Holdings, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | $2.7b | $-267.7m | $-111.5m | -10.1% | — |
| 2018 | $2.5b (-4.6%) | $-146.8m (45.2%) | $-304.5m (-173.1%) | -5.8% (42.5%) | — |
| 2019 | $6.0m (-99.8%) | $-152.0m (-3.5%) | $-75.6m (75.2%) | -2535.1% (-43622.9%) | — |
| 2020 | $159.7m (2564.6%) | $-36.9m (75.7%) | $-3.0m (96.0%) | -23.1% (99.1%) | — |
| 2021 | $305.4m (91.2%) | $34.6m (193.6%) | $98.3m (3389.6%) | 11.3% (149.0%) | — |
| 2022 | $437.9m (43.4%) | $181.5m (424.5%) | $144.3m (46.9%) | 41.4% (265.9%) | — |
| 2023 | $582.0m (32.9%) | $128.9m (-29.0%) | $219.1m (51.8%) | 22.1% (-46.6%) | — |
| 2024 | $714.7m (22.8%) | $145.5m (12.9%) | $218.7m (-0.2%) | 20.4% (-8.1%) | — |
| 2025 | $868.5m (21.5%) | $158.7m (9.1%) | $347.9m (59.1%) | 18.3% (-10.2%) | — |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.